Education
About Us
Working with TipRanks
Follow Us
Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
RESEARCH TOOLSreports
Total Valuation
Aurobindo Pharma Ltd has a market cap or net worth of ₹690.05B. The enterprise value is ₹864.15B.
Market Cap₹690.05B
Enterprise Value₹864.15B
Share Statistics
Aurobindo Pharma Ltd has 580,801,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding580,801,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aurobindo Pharma Ltd’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 20.36%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)20.36%
Return on Capital Employed (ROCE)0.32
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.64
Inventory Turnover1.32
Valuation Ratios
The current PE Ratio of Aurobindo Pharma Ltd is 20.56. Aurobindo Pharma Ltd’s PEG ratio is 0.32.
PE Ratio20.56
PS Ratio―
PB Ratio2.19
Price to Fair Value2.19
Price to FCF-57.88
Price to Operating Cash Flow26.79
PEG Ratio0.32
Income Statement
In the last 12 months, Aurobindo Pharma Ltd had revenue of 290.02B and earned 31.73B in profits. Earnings per share was 54.16.
Revenue290.02B
Gross Profit160.16B
Operating Income104.50B
Pretax Income43.80B
Net Income31.73B
EBITDA61.79B
Earnings Per Share (EPS)54.16
Cash Flow
In the last 12 months, operating cash flow was 23.47B and capital expenditures -14.96B, giving a free cash flow of 8.51B billion.
Operating Cash Flow23.47B
Free Cash Flow8.51B
Free Cash Flow per Share14.66
Dividends & Yields
Aurobindo Pharma Ltd pays an annual dividend of ₹1.5, resulting in a dividend yield of 0.38%
Dividend Per Share₹1.5
Dividend Yield0.38%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change15.15%
50-Day Moving Average1.14K
200-Day Moving Average1.31K
Relative Strength Index (RSI)64.86
Average Volume (3m)37.77K
Important Dates
Aurobindo Pharma Ltd upcoming earnings date is May 30, 2025, TBA Not Confirmed.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 30, 2025
Ex-Dividend DateFeb 20, 2024
Financial Position
Aurobindo Pharma Ltd as a current ratio of 1.98, with Debt / Equity ratio of 27.29%
Current Ratio1.98
Quick Ratio1.18
Debt to Market Cap0.10
Net Debt to EBITDA0.53
Interest Coverage Ratio36.07
Taxes
In the past 12 months, Aurobindo Pharma Ltd has paid 12.11B in taxes.
Income Tax12.11B
Effective Tax Rate0.28
Enterprise Valuation
Aurobindo Pharma Ltd EV to EBITDA ratio is 11.08, with an EV/FCF ratio of -60.76.
EV to Sales2.36
EV to EBITDA11.08
EV to Free Cash Flow-60.76
EV to Operating Cash Flow28.13
Balance Sheet
Aurobindo Pharma Ltd has ₹63.26B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹63.26B billion.
Cash & Marketable Securities₹63.26B
Total Debt₹0.00
Net Cash-₹63.26B
Net Cash Per Share-₹108.92
Tangible Book Value Per Share₹439.94
Margins
Gross margin is 54.25%, with operating margin of 36.03%, and net profit margin of 10.94%.
Gross Margin54.25%
Operating Margin36.03%
Pretax Margin15.10%
Net Profit Margin10.94%
EBITDA Margin21.30%
EBIT Margin16.03%
Analyst Forecast
The average price target for Aurobindo Pharma Ltd is ₹1,342.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,342.50
Price Target Upside22.33% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―